[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338598-105":59,"doc-detail-338598-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","loss-of-heterozygosity-loh-affecting-hla-genes-in-breast-cancer-clinical-relevance-and-therapeutic-opportunities","Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer - Clinical Relevance and Therapeutic Opportunities","","Major histocompatibility complex (MHC) class-I molecules (HLA class-I) are central to adaptive immunity against cancer by presenting tumor neoantigens to cytotoxic T cells. Total or partial HLA loss can impair immune detection and killing of cancer cells. Loss of heterozygosity (LOH) is a common irreversible alteration, and LOH involving HLA genes at chromosome 6 is linked to breast cancer progression and reduced immunotherapy responses. This review discusses LOH-HLA roles in immune escape, tumor progression, and therapeutic targeting for improved biomarkers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/loss-of-heterozygosity-loh-affecting-hla-genes-in-breast-cancer-clinical-relevance-and-therapeutic-opportunities/338598/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/loss-of-heterozygosity-loh-affecting-hla-genes-in-breast-cancer-clinical-relevance-and-therapeutic-opportunities/338598.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role do HLA class-I molecules play in anti-cancer immunity?","Question",{"text":113,"@type":114},"HLA class-I molecules present tumor neoantigens to cytotoxic T cells, triggering an antitumor cytotoxic response. Loss of HLA can reduce immune recognition and killing of tumor cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does loss of heterozygosity (LOH) involving HLA genes affect cancer progression?",{"text":118,"@type":114},"LOH affecting chromosome 6 regions containing HLA genes (LOH-HLA) can cause loss of an HLA haplotype. It is linked to cancer progression and a weaker response to cancer immunotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is LOH-HLA important for cancer immunotherapy outcomes?",{"text":122,"@type":114},"LOH-HLA can drive immune escape by reducing effective antigen presentation. It has been reported as a mechanism of resistance after treatment with immune checkpoint inhibitors or adoptive T-cell therapies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338598,1790165482,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Review  \nLoss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities  \nMaría Antonia Garrido 1, Alba Navarro-Ocón 2,3, Víctor Ronco-Díaz 2,4, Nicolás Olea 1,3,5,6 and Natalia Aptsiauri 2,3, *  \nCitation: Garrido, M.A.;  \nNavarro-Ocón, A.; Ronco-Díaz, V.; Olea, N.; Aptsiauri, N. Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities. Genes 2024, 15, 1542 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)genes15121542  \nAcademic Editor: Christos K. Kontos  \nReceived: 3 November 2024  \nRevised: 22 November 2024  \nAccepted: 26 November 2024  \nPublished: 28 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Radiology Service, Virgen de la Nieves University Hospital, 18014 Granada, Spain; [nona_garrido@hotmail.com](nona_garrido@hotmail.com) (M.A.G.); [nolea@ugr.es](nolea@ugr.es) (N.O.)  \n2 Department of Biochemistry, Molecular Biology III and Immunology, School of Medicine, University of Granada, 18016 Granada, Spain; [albanaoc@correo.ugr.es](albanaoc@correo.ugr.es) (A.N.-O.); [victor.ronco@genyo.es](victor.ronco@genyo.es) (V.R.-D.)  \n3 Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain  \n4 Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), 18016 Granada, Spain  \n5 Department of Radiology and Physical Medicine, School of Medicine, University of Granada,  \n18016 Granada, Spain  \n6 CIBER of Epidemiology and Public Health (CIBERSP), 28034 Madrid, Spain  \n* Correspondence: naptsiauri@ugr.es  \nAbstract: Major histocompatibility complex (MHC) class-I molecules (or Human Leucocyte Antigen class-I) play a key role in adaptive immunity against cancer. They present specific tumor neoantigens to cytotoxic T cells and provoke an antitumor cytotoxic response. The total or partial loss of HLA molecules can inhibit the immune system’s ability to detect and destroy cancer cells. Loss of heterozygosity (LOH) is a common irreversible genetic alteration that occurs in the great majority of human tumors, including breast cancer. LOH at chromosome 6, which involves HLA genes (LOH-HLA), leads to the loss of an HLA haplotype and is linked to cancer progression and a weak response to cancer immunotherapy. Therefore, the loss of genes or an entire chromosomal region which are critical for antigen presentation is of particular importance in the search for novel prognostic and clinical biomarkers in breast cancer. Here, we review the role of LOH-HLA in breast cancer, its contribution to an understanding of cancer immune escape and tumor progression, and discuss how it can be targeted in cancer therapy.  \nKeywords: HLA class-I; LOH HLA; cancer immune escape; breast cancer  \n1. Introduction  \nMalignant transformation is accompanied by an accumulation of somatic mutations, genetic instability and chromosomal alterations. Cancer immune escape associated with these aberrations is a serious obstacle in developing effective anticancer therapeutic strategies. Recent advances in the clinical application of newly designed protocols of cancer immunotherapy, including immune checkpoint inhibition and T-cell-mediated therapies, have confirmed that cancer immune evasion mechanisms remain responsible for the resistance to treatment and poor survival [1] . One of these mechanisms is a lack of normal tumor antigen presentation caused by altered HLA class-I (HLA-I) expression on tumor cells. It renders malignant cells invisible to cytotoxic T cells (CTLs) and helps cancers evade immune sur","cbCaikweJ2MacqxH","https://ap.wps.com/l/cbCaikweJ2MacqxH","pdf",2033963,13,"English","# Introduction\n## Importance of HLA Class-I Loss in Tumor Rejection and Immune Escape","[{\"question\":\"What role do HLA class-I molecules play in anti-cancer immunity?\",\"answer\":\"HLA class-I molecules present tumor neoantigens to cytotoxic T cells, triggering an antitumor cytotoxic response. Loss of HLA can reduce immune recognition and killing of tumor cells.\"},{\"question\":\"How does loss of heterozygosity (LOH) involving HLA genes affect cancer progression?\",\"answer\":\"LOH affecting chromosome 6 regions containing HLA genes (LOH-HLA) can cause loss of an HLA haplotype. It is linked to cancer progression and a weaker response to cancer immunotherapy.\"},{\"question\":\"Why is LOH-HLA important for cancer immunotherapy outcomes?\",\"answer\":\"LOH-HLA can drive immune escape by reducing effective antigen presentation. It has been reported as a mechanism of resistance after treatment with immune checkpoint inhibitors or adoptive T-cell therapies.\"}]","Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer - Clinical Relevance and Therapeutic Opportunities | PDF",1790024405,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7642ec9efd89c62977159e96a542a0d.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e774a65adba77bef320f058b844212af.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/042f5f6976f03d41509302b7ee8e9159.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa7ee60d8e6d6d8e473bebd1278b3aeb.webp",980,1385]